Background: Liver kinase B1 (LKB1) is a tumor suppressor in lung adenocarcinoma (LADC). We investigated the proteomic profiles of 45 LADC cell lines with and without LKB1 inactivation. Carbamoyl phosphate synthetase 1 (CPS1), the first ratelimiting mitochondrial enzyme in the urea cycle, was distinctively overexpressed in LKB1-inactivated LADC cell lines. We therefore assessed the role of CPS1 and its clinical relevance in LKB1-inactivated LADC. Methods: Mass spectrometric profiling of proteome and metabolome and function of CPS1 were analyzed in LADC cell lines. CPS1 and LKB1 expression in tumors from 305 LADC and 160 lung squamous cell carcinoma patients was evaluated by immunohistochemistry. Kaplan-Meier and Cox regression analyses were applied to assess the association between overall survival and CPS1 and LKB1 expression. All statistical tests were two-sided. Results: CPS1 knockdown reduced cell growth, decreased metabolite levels associated with nucleic acid biosynthesis pathway, and contributed an additive effect when combined with gemcitabine, pemetrexed, or CHK1 inhibitor AZD7762. Tissue microarray analysis revealed that CPS1 was expressed in 65.7% of LKB1-negative LADC, and only 5.0% of LKB1-positive LADC. CPS1 expression showed statistically significant association with poor overall survival in LADC (hazard ratio ¼ 3.03, 95% confidence interval ¼ 1.74 to 5.25, P < .001). Conclusions: Our findings suggest functional relevance of CPS1 in LKB1-inactivated LADC and association with worse outcome of LADC. CPS1 is a promising therapeutic target in combination with other chemotherapy agents, as well as a prognostic biomarker, enabling a personalized approach to treatment of LADC.
biologically distinct from cancer with functional LKB1 and that the loss of LKB1 uniquely confers invasive and metastatic properties (9, 10) . In addition, coclinical trials with genetically engineered mouse models demonstrated that LKB1-deficient lung tumors impaired the response of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors to chemotherapy (9, 11) . LKB1 is a master regulator of various cellular responses including energy metabolism, cell polarity, and cell growth through direct phosphorylation and activation of AMP-activated protein kinase (AMPK)-related protein kinases (12, 13) . While various pathways regulated by LKB1 can play a pleiotropic role in cancer initiation and progression, no therapies are currently available for clinical use that specifically target LKB1 inactivation (14) . Therefore, elucidation of the functional mechanism(s) associated with LKB1 inactivation has immense translational relevance (15) .
In this study, we initially compared the proteomic profiles of 45 LADC cell lines to identify molecular features associated with LKB1 inactivation. Carbamoyl phosphate synthase 1 (CPS1) was identified as a markedly increased protein in LKB1-inactivated LADC cell lines. CPS1 is the first rate-limiting enzyme in the urea cycle, converting ammonium into carbamoyl phosphate, and plays an intricate role in arginine metabolism and pyrimidine metabolism (16) (17) (18) (19) . We further investigated the effect of CPS1 through knockdown experiments and the consequences of its overexpression on survival in LADC.
Methods

LADC Cell Lines
Proteomic analysis of whole cell lysates (WCE), cell surface proteins, and conditioned media from 45 LADC cell lines was performed using mass spectrometry as previously described (20) . Details are provided in the Supplementary Methods (available online). Cell transfection, viral transduction, cell viability assay, cell cycle analysis, ammonia assay, metabolomics profiling, real-time polymerase chain reaction (RT-PCR), and immunoblot analysis are described in the Supplementary Methods (available online).
Tissue Microarrays
The tissue microarrays used in this study comprised 305 surgically resected LADCs and 160 squamous cell carcinoma tumor specimens collected under an institutional review board protocol of The University of Texas MD Anderson Cancer Center and archived as formalin-fixed, paraffin-embedded specimens in The University of Texas Specialized Program of Research Excellence thoracic tissue bank at The University of Texas MD Anderson Cancer Center. All patients gave written informed consent. Details are provided in the Supplementary Methods (available online).
Statistical Analysis
Categorical data were compared by Fisher's exact test or chisquare test. Continuous variables were compared by MannWhitney U test or unpaired t test. Pearson's correlation was applied to assess the linear association between two variables.
Survival analysis was performed with 262 LADC samples with available survival data from the tissue microarray and an independent gene expression data set of 403 LADCs from The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/) (2) using Kaplan-Meier survival curves. The log-rank test was used to evaluate the statistical significance of differences of survival curves. Overall survival was defined as the time from the date of the initial surgery (tissue microarray) and the initial pathologic diagnosis (the TCGA data set) to the date of death or last follow-up, at which point the data were censored. Cox proportional hazards model analyses (21) were performed to adjust for covariates of statistical significance in univariate analysis, including sex, age, smoking status, stage, and CPS1 and LKB1 expression, and to estimate the relative hazard of mortality over the follow-up period. Using R statistical software (version 3.2.3), we generated the time-dependent covariates by creating interactions of the predictors and a function of survival time and included the covariates in the model. When any of the timedependent covariates are significant, then those predictors are not proportional. Details on determination of optimal cutoff values for age and CPS1 and LKB1 mRNA expression levels are provided in the Supplementary Methods (available online).
Statistical analysis was done using R and GraphPad Prism software (version 6.0, GraphPad Software, Inc., La Jolla, CA). We used a two-sided statistical significance level of .05 for all statistical analyses.
Results
Comparison of Proteomic Profiling of LKB1-Inactivated and -Intact LADC Cell Lines
Expression levels of LKB1 protein were determined by immunoblotting across 48 LADC cell lines that encompass the known genomic heterogeneity associated with LADC with respect to known mutations (Supplementary Figure 1, Table 1 , available online). Three cell lines with indeterminate LKB1 status were excluded from further analysis. LKB1 inactivation status was statistically significantly associated with epidermal growth factor receptor (EGFR) and KRAS mutational status (P ¼ .01, chi-square test), supporting previous studies (6), but was not statistically significant related to phenotypic characteristics such as cell morphology or invasion properties (data not shown) (23) .
We then performed quantitative proteomic profiling of three cellular protein compartments (whole cell extract [WCE] , cell surface proteins, and conditioned media) of the 45 LADC cell lines with known LKB1 status using mass spectrometry as previously described (20, 23, 24) . A total of 213, 325, and 200 proteins were found to be increased in WCE, cell surface proteins, and conditioned media, respectively, from LKB1-inactivated cell lines compared with LKB1-intact cell lines (Supplementary  Table 2 , available online). Ingenuity Pathway Analysis (IPA: http://www.ingenuity.com/) revealed that the increased proteins in LKB1-inactivated cell lines were highly associated with metabolic pathways, including mitochondrial dysfunction pathways (Supplementary Figure 2 , available online), suggesting profound effects of LKB1 on metabolism in LADC. Interestingly, expression levels of CPS1 protein were strikingly higher in all three cellular compartments of LKB1-inactivated cell lines than in LKB1-intact cell lines (P < .001 for WCE, P ¼ .02 for cell surface, and P ¼ .03 for media, Mann-Whitney U test) ( Figure 1A ; Supplementary Table 2, available online). In addition, mRNA expression levels of CPS1 (23) were statistically significantly increased in LKB1-inactivated cell lines (P < .001, Mann-Whitney U test) ( Figure 1B ). Increased protein expression of CPS1 with LKB1 inactivation was further confirmed by immunoblotting in LKB1-inactivated and LKB1-intact LADC cell lines ( Figure 1C ).
To determine whether CPS1 expression is regulated by LKB1, we induced overexpression and knockdown of LKB1 in LADC cell lines. Overexpression of LKB1 substantially repressed CPS1 protein expression in H1437 and H1944 cell lines ( Figure 1D ), while knockdown of LKB1 did not increase CPS1 expression in LKB1-intact cell lines H2009 and H1793 ( Figure 1E ), suggesting that CPS1 is negatively regulated by LKB1 and that additional regulatory mechanisms are required for induction of CPS1. On the other hand, overexpression of CPS1 did not affect LKB1 expression (Supplementary Figure 3 , available online). Figure 2B ). CPS1 knockdown had no statistically significant effect on G1, G2/M, or sub-G1 population, suggesting that cell cycle arrest and apoptosis were not associated with the reduction of cell proliferation. The findings were further supported by Annexin V assay ( Figure 2D ). While recent studies C and E) H2030 cell lysates were used as a CPS1-positive control. CPS1 ¼ carbamoyl phosphate synthetase 1; LKB1 ¼ liver kinase B1.
Analysis of CPS1 Function in LADC Cell Lines
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indicated that ammonia induces autophagy (25,26), we did not observe the occurrence of autophagy in cells with silenced CPS1 ( Figure 2E ). As CPS1 is involved in the arginine and pyrimidine metabolism pathways, we examined metabolites associated with these pathways during CPS1 knockdown using mass spectrometry. Twenty-eight metabolites were identified with high confidence on the basis of NIST MSMS and The Human Metabolome Database (http://www.hmdb.ca/) fragmentation matching. Interestingly, most of the identified metabolites in both purine and pyrimidine metabolism pathways, as well as arginine, were consistently decreased in CPS1 knockdown H1437 and H1944 cells compared with control cells from those cell lines ( Figure 3A) .
While cell cycle arrest at G2/M phase was not observed in siCPS1-treated cells ( Figure 2C ), supplementation of deoxynucleotide (dNTP) statistically significantly rescued cell growth in cells with siCPS1 treatment (Figure 3B ), leading us to speculate that CPS1 knockdown would deplete the pool of metabolites in the nucleic acid synthesis pathways and thus would have additive effects on growth inhibition in combination with other chemotherapy agents. We examined the effects of CPS1 knockdown combined with gemcitabine and pemetrexed, which 
interfere with DNA synthesis pathways and are frequently used to treat LADC (27) , as well as with CHK1 inhibitor AZD7762, to which LKB1-deficient lung cancer was recently shown to be sensitive (28) . CPS1 knockdown showed statistically significant additive effects in all drug combinations in the LKB1-inactivated cell lines H1437 and H1944 ( Figure 3C ) but not in the LKB1-intact cell line H2009, indicating the potential of CPS1 as a therapeutic target alone or combined with these conventional chemotherapy agents or with DNA damage checkpoint inhibitors in LKB1-inactivated LADC.
To gain further insights into molecular pathways perturbed by CPS1 knockdown, we performed PrimePCR array (Biorad, Hercules, CA), which consists of 376 cancer-related genes in H1437 and H1944 cells with or without CPS1 knockdown. Eightyone genes were more than 25% increased or decreased after CPS1 knockdown in both cell lines (Supplementary Table 3 , available online). Interestingly, pathway analysis using IPA revealed that among top 13 statistically significant pathways (identification of > 10% genes in the pathway and -log(P value) > 8), eight pathways were associated with Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway: role of JAK family kinases in interleukin-6 (IL-6) cytokine signaling, ciliary neurotrophic factor (CNTF) signaling, JAK/ STAT signaling, STAT3 pathway, role of JAK1 and JAK3 in gamma chain cytokine signaling, IL-15 signaling, cluster of differentiation 40 (CD40) signaling, and mouse embryonic stem cell pluripotency ( Figure 4A ). While mRNA expression of suppressor of cytokine signaling 1 (SOCS1), a negative regulator of the JAK/STAT signaling pathway, was increased by CPS1 knockdown, mRNA expression levels of several key genes in the JAK/ STAT signaling pathway, including JAK1, STAT3, and interleukin 6 signal transducer (IL6ST), were consistently decreased ( Figure  4B ), suggesting that CPS1 knockdown would suppress the JAK/ STAT signaling pathway.
CPS1 Expression and Overall Survival in LADC
To determine the clinical significance of CPS1 in lung cancer, we examined CPS1 and LKB1 protein expression in LADC and squamous cell carcinoma tissues using a tissue microarray. CPS1 expression was found predominantly in the cytoplasm. Figure 5A depicts representative images of LADC specimens with negative CPS1 and positive LKB1 (Pt #1) and with positive CPS1 and negative LKB1 (Pt #2). In total, 56 (18.4%) of 305 LADC tumors were positively stained with CPS1 (Table 1 ). CPS1 protein expression was statistically significantly and inversely correlated with LKB1 protein expression: CPS1 was positive in 44 (65.7%) LKB1-negative LADCs but only 12 (5.0%) LKB1-positive LADCs (P < .001, chi-square test), further confirming the findings in LADC cell lines. The CPS1 positivity was statistically significantly associated with smoking status (P ¼ .003, chi-square test), but not with sex, age, or mutational status for EGFR and KRAS (Table 1) . On the other hand, only two (1.3%) of 160 squamous cell carcinoma tumors were positively stained with CPS1 (Supplementary Table 4 , available online).
Kaplan-Meier analysis in 262 LADC patients revealed that positive CPS1 expression was statistically significantly associated with worse overall survival (P < .001, log-rank test) ( Figure 5B ). Of note, CPS1 positivity was statistically significantly associated with poor overall survival in stage I LADC (P < .001, log-rank test) ( Figure 5B) . A univariate Cox regression analysis revealed that CPS1 expression, LKB1 expression, stage, and sex were statistically significantly associated with overall survival (Table 2) . Multivariable Cox regression analysis indicated that CPS1 expression was the strongest independent predictor of overall survival (P < .001, hazard ratio [HR] ¼ 3.03, 95% confidence interval [CI] ¼ 1.74 to 5.25), while LKB1 expression was not statistically significantly associated with overall survival ( Figure 5C and Table 2 ).
The prognostic potential of CPS1 was further examined in an independent cohort of 403 LADCs in the TCGA data set. mRNA levels of CPS1 were statistically significantly higher in LADC tissues than in normal adjacent tissues (P ¼ .002, unpaired t test) ( Figure 5D ; Supplementary Figure 6 , available online).While LKB1 mRNA expression levels in tumor tissues were not statistically significantly lower than in normal tissues, CPS1 mRNA and LKB1 mRNA expression levels showed a statistically significant inverse correlation (Pearson correlation coefficient ¼ À0.33, P < .001) (Supplementary Figure 6 , available online). Concordant with the findings in the tissue microarray, Kaplan-Meier survival curves indicated that high CPS1 mRNA expression was statistically significantly associated with worse overall survival (P ¼ .004, log-rank test) ( Figure 5E ). In addition, high CPS1 mRNA expression was a statistically significant and independent predictor of overall survival in both univariate and multivariable Cox regression analyses (univariate analysis: HR ¼ 1.96, 95% CI ¼ 1.22 to 3.15, P ¼ .005; multivariable analysis: HR ¼ 2.31, 95% CI ¼ 1.28 to 4.16, P ¼ .005), while LKB1 mRNA expression was not statistically significantly associated with overall survival (Table 3) .
Discussion
In this study we analyzed the proteomic profiles of 45 LADC cell lines to identify molecular features associated with LKB1 inactivation. Protein signatures associated with LKB1 inactivation comprised proteins involved in metabolism, including CPS1, which showed strikingly higher expression levels in LKB1-inactivated cell lines than in LKB1-intact cell lines. CPS1 knockdown reduced cell growth, decreased levels of metabolites associated with nucleic acid biosynthesis, and showed an additive beneficial effect when combined with conventional chemotherapy agents or DNA damage checkpoint inhibitors. In addition, CPS1 expression at both protein and mRNA levels was statistically significantly and independently associated with poor overall survival in LADC. Our findings suggest that CPS1 is a promising therapeutic target and prognostic indicator in LADC.
CPS1 is a multidomain mitochondrial enzyme protein, catalyzing the first committed step of the urea cycle for ammonia detoxification and disposal (16, 29) . CPS1 is expressed mainly in intestinal epithelial cells and liver cells, as well as several types of cancer including liver, colorectal, stomach, cervical, and pancreatic cancer (29) (30) (31) (32) (33) (34) (35) (36) (37) . Although expression of CPS1 protein has not been well studied in lung cancer, Kaufman ARTICLE (38) . In addition, Skoulidis et al. performed an integrative analysis of genomic, transcriptomic, and proteomic profiling of KRAS-mutant LADC and showed CPS1 to be one of the overexpressed genes in a subset of LADCs harboring genetic events in KRAS and LKB1 (39) . This previous evidence further supports the CPS1 protein expression in LKB1-inactivated LADC demonstrated in this study through in-depth proteomic profiling of LADC cell lines and tissue microarray analysis.
CPS1 plays a crucial role in removing excessive ammonia by converting ammonium into carbamoyl phosphate in the liver (16) , which is a de novo resource of arginine (19) and potential substrate of pyrimidine synthesis (17, 18) . We demonstrated that knockdown of CPS1 induced accumulation of ammonia, a decrease of metabolites in nucleic acid synthesis pathways, and a decrease of arginine in LKB1-inactivated LADC cell lines. While CPS1 is implicated in pyrimidine synthesis pathways, our metabolomic profiling suggested that metabolites in both pyrimidine and purine synthesis pathways were decreased in cells with siCPS1 treatment. This can be possibly explained by decreased levels of glutamic acid, a prominent intermediate in nitrogen disposal ( Figure 3A) , because accumulation of ammonia would result in excessive buildup of ammonia and a reduction in metabolites directly associated with nitrogen removal.
Our findings suggest that the decrease of metabolites in the nucleic acid synthesis pathways was associated with siCPS1-induced inhibition of cell growth, and we observed that CPS1 knockdown had a beneficial effect when combined with conventional chemotherapy agents or a DNA damage checkpoint inhibitor. Liu and colleagues have recently indicated that LKB1-mutant lung cancers are vulnerable in nucleotide biosynthesis pathways and sensitive to deoxythymidylate kinase inhibition (28) . Therefore, targeting CPS1 in combination with deoxythymidylate kinase also might have promising therapeutic potential in LKB1-inactivated LADC.
Quantitative RT-PCR analyses suggest possible suppression of the JAK/STAT pathway by CPS1 knockdown. Recent studies have reported activation of the JAK/STAT pathway in sex-determining region Y box 2 (SOX2)-driven, LKB1-deficient mouse model of squamous cell lung cancer (47) and increase of IL-6 production and subsequent activation of STAT3 in LKB1-deficient mouse model of LADC (48, 49) . As IL-6/JAK/STAT signaling axis plays important roles in cell proliferation, survival, invasion, chemoresistance, and immunosuppression, (48, (50) (51) (52) (53) , targeting CPS1 might alter tumor microenvironment and improve efficiency of immunotherapy.
Regarding the clinical relevance of CPS1 in LADC, we demonstrated that increased CPS1 expression at both protein and (n ¼ 423) and adjacent normal tissues (n ¼ 56) in The Cancer Genome Atlas (TCGA) data set. P values were calculated by unpaired t test. E) Kaplan-Meier survival curves of LADC patients in the TCGA data set stratified according to mRNA expression of CPS1 (CPS1-low n ¼ 341; CPS1-high n ¼ 62). B, C, and E) P values were calculated by log-rank test. All statistical tests were two-sided. CPS1 ¼ carbamoyl phosphate synthetase 1; LKB1 ¼ liver kinase B1.
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mRNA levels was statistically significantly associated with poor overall survival. Increased CPS1 expression is also associated with poor prognosis in cervical carcinoma (37) and rectal cancer (33) . Of note, positive immunostaining of CPS1 was statistically significantly associated with poorer overall survival in stage I LADC. The survival benefit of adjuvant chemotherapy in stage I non-small cell lung cancer is controversial, while trials have shown that cisplatin-based adjuvant chemotherapy in clinic significantly improved the five-year survival rate in stage II and IIIa non-small cell lung cancer (27) . Therefore, CPS1 would be a promising molecular biomarker of poor prognosis in LADC and could enable us to personalize treatment of the disease.
A potential limitation of the study is the lack of CPS1 inhibitor, which hampers immediate application to therapy. However, it has been reported that sirtuin 5 (SIRT5) deacetylates and desuccinylates CPS1 protein and enhances CPS1 activity (43, 44) . Thus, pharmacologic inhibition of SIRT5 might be a strategy for targeting CPS1. It has been recently demonstrated that the antidiabetic drug metformin, an established AMPK activator, reduced the mouse SIRT5 protein both in cultured hepatocytes and in livers in vivo (45) . In addition, phenformin, a mitochondrial inhibitor and analogue of metformin, selectively reduced tumor volume and prolonged survival in a mouse model of lung cancer with KRAS and LKB1 mutations (46), suggesting repurposing metformin and related agents as a promising strategy in the treatment of LKB1-inactivated LADC.
In conclusion, proteomic characterization of LKB1-inactivated LADC cell lines identified CPS1 as a therapeutic target, expanding potential therapeutic options in combination with conventional chemotherapy agents while revealing a potential biomarker for precision medicine in LADC. 
